Additionally, Polatuzumab vedotin—a CD79b-targeted antibody–drug conjugate—has shown enhanced efficacy when combined with R-CHP in DLBCL patients, particularly in those with the ABC (non-GCB) subtype. Here, CD79B is linked to diffuse large B-cell lymphoma.